Summary of COVID-19 bebtelovimab studies


1. Molina et al., Real-World Evaluation of Bebtelovimab Effectiveness During the Period of COVID-19 Omicron Variants including BA.4/BA.5
9,162 patient bebtelovimab early treatment PSM study: 57% lower mortality (p=0.14), 59% lower ICU admission (p=0.05), 56% lower hospitalization (p<0.0001), and 33% higher progression (p=0.001).
Retrospective 3,739 patients treated with bebteloviman in the USA and matched controls, showing lower mortality and hospitalization with treatment, but higher emergency department visits.
Apr 2023, Int. J. Infectious Diseases, https://www.sciencedirect.com/science/article/pii/S1201971223005258, https://c19p.org/molina2

2. Dryden-Peterson et al., Bebtelovimab for high-risk outpatients with early COVID-19 in a large US health system
754 patient bebtelovimab early treatment study: 86% lower mortality (p=0.25), 43% lower combined mortality/hospitalization (p=0.14), and 29% lower hospitalization (p=0.53).
Retrospective 377 outpatients in the USA and matched controls, showing lower hospitalization/mortality with bebtelovimab treatment, without statistical significance. Notably, none of the patients that died in the control group were hospitalized within 14 days (later hospitalization is not reported). There may be a difference in the populations in terms of propensity to receive SOC.
Oct 2022, Open Forum Infectious Diseases, https://academic.oup.com/ofid/advance-article/doi/10.1093/ofid/ofac565/6775265, https://c19p.org/drydenpeterson2

3. Sridhara et al., Lack of effectiveness of Bebtelovimab monoclonal antibody among high-risk patients with SARS-Cov-2 Omicron during BA.2, BA.2.12.1 and BA.5 subvariants dominated era
2,182 patient bebtelovimab early treatment PSM study: 86% lower mortality (p=0.25), 25% lower combined mortality/hospitalization (p=0.31), and 11% lower hospitalization (p=0.78).
PSM retrospective 19,778 high-risk outpatients in the USA, showing no significant difference in outcomes with bebtelovimab treatment.
Apr 2023, PLOS ONE, https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0279326, https://c19p.org/sridhara

4. Kip et al., Evolving Real-World Effectiveness of Monoclonal Antibodies for Treatment of COVID-19
2,571 patient bebtelovimab early treatment study: 20% lower combined mortality/hospitalization (p=0.65).
Retrospective 2,571 patients treated with mAbs in the USA, and 5,135 control patients, showing lower combined mortality/hospitalization for bamlanivimab, bamlanivimab/etesevimab, casirivimab/imdevimab, sotrovimab, and bebtelovimab, with statistical significance only for casirivimab/imdevimab.
Apr 2023, Annals of Internal Medicine, https://www.acpjournals.org/doi/10.7326/M22-1286, https://c19p.org/kipbt

5. Dougan et al., Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19
714 patient bebtelovimab early treatment RCT: 25% faster recovery and 4% improved viral clearance (p<0.0001).
RCT showing improved viral clearance with bebtelovimab. Results refer to the placebo controlled portion of the trial.
Mar 2022, medRxiv, https://www.medrxiv.org/content/10.1101/2022.03.10.22272100, https://c19p.org/dougan2

6. Lilly et al., A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness
380 patient bebtelovimab early treatment RCT: 36% improved viral clearance (p=0.07).
RCT with 127 bamlanivimab, etesevimab, and bebtelovimab patients, 125 bebtelovimab patients, and 128 control patients, showing no significant differences in hospitalization and mortality. Viral clearance was improved although not statistically significant. NCT04634409.
Feb 2022, Lilly, https://clinicaltrials.gov/ct2/show/NCT04634409, https://c19p.org/blaze4